A recent example is anlotinib, which inhibits VEGFR1, VEGFR2/KDR, VEGFR3, c-kitPDGFR1 and FGFR [53], which is an example of Chinese developed drugs, being registered for treatment of NSCLC and soft tissue sarcoma [53,54]. This evidence concerns the gene KDR and non-small cell lung carcinoma.